GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
K

Klaria Pharma Holding AB (publ) KLAR.ST · SEK

Health Care · Nasdaq Stockholm · 🇸🇪 Sweden

Compare

0.51

-2.29%

Close of 9 Nov 2026, in SEK

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Klaria Pharma Holding AB (publ)

Its shares trade on Nasdaq Stockholm under the ticker KLAR.ST. It has been listed since 21 October 2015. In the fiscal year to 31 December 2025, it reported revenue of SEK 9.0m and a net loss of SEK 38.9m. At that date it held total assets of SEK 40.8m and shareholders' equity of −SEK 3.9m.

Klaria Pharma Holding AB engages in the development and commercialization of pharmaceutical products for migraine and cancer-related pain. The company is headquartered in Uppsala, Uppsala. The company went IPO on 2015-10-21. Through its group subsidiaries, the Company is active in developing and commercializing therapeutic drugs and treatment methods in the fields of migraine and pain related to cancer based on a patented drug delivery platform in the form of an alginate-based polymer film, which facilitates rapid and reliable transmucosal absorption via a muco-adhesive film. The firm operates Klaria Pharma AB as a wholly owned subsidiary.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
21 Oct 2015
Website
klaria.com ↗

Leadership

Pay as last reported

  • Mr. Fredrik HubinetteChairman of the Board, Acting Chief Executive Officer, since 2020
  • Mr. Hans RichterChief Financial Officer
  • Mr. Leif IngemarssonChief Technical Officer
  • Mr. Scott BoyerChief Scientific Officer, Director, since 2019
  • Ms. Kristina Liden MascherHead of Clinical Operations
  • Mr. Michael BrobjerDirector

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in Uppsala, Sweden, with a focus on pharmaceutical development and commercialization.
  • Operates through a wholly owned subsidiary, Klaria Pharma AB, for its business activities.
  • Utilizes a patented alginate-based polymer film for rapid transmucosal absorption in drug delivery.

Weaknesses

  • Relies on a single patented drug delivery platform for its therapeutic products.
  • Limited to specific therapeutic areas: migraine and cancer-related pain.
  • IPO occurred in 2015, indicating a relatively recent market entry.

Opportunities

  • Expansion of the patented drug delivery platform to additional therapeutic areas.
  • Growth potential in the pharmaceutical market for migraine and cancer pain treatments.
  • Potential for partnerships or acquisitions to broaden product portfolio.

Threats

  • Competition from other pharmaceutical companies in migraine and cancer pain treatments.
  • Regulatory challenges in the pharmaceutical industry affecting product approvals.
  • Dependence on a single drug delivery platform may limit adaptability to market changes.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.